Sengöz Tarık, Sürücü Erdem, Demir Yusuf, Derebek Erkan
Balıkesir Government Hospital, Department of Nuclear Medicine, Balıkesir, Turkey.
Mol Imaging Radionucl Ther. 2012 Dec;21(3):103-9. doi: 10.4274/Mirt.25744. Epub 2012 Dec 20.
To investigate whether the factors related to the patient and the disease have any effect on the success of ablation therapy in patients with differentiated thyroid cancer who have received I-131 ablation therapy.
All the patients with differentiated thyroid cancer were referred for I-131 ablation therapy after thyroidectomy between July 2007 and September 2009. The patients had at least six months of follow-up. Age, gender, type of tumor, presence of capsule invasion, size of tumor, number of the tumors, localization of the tumor, invasion of thyroid capsule, lymph/vessel invasion, presence of metastatic lymph nodes, type of surgery, preablation values of thyroglobulin (Tg), AntiTg, TSH, surveys for the evaluation of metastatic disease, (thyroid and bone scintigraphy, neck and abdominal ultrasonography, chest and brain computerized tomography), administered dose, postablation I-131 whole body scan (WBS) and diagnostic I-131 WBS, neck USG, values of Tg and AntiTg at the 6th month were recorded. The presence of residual thyroid activity on the 6th month diagnostic I-131 WBS image was accepted as the criterion for ablation success.
191 patients with differentiated thyroid cancer were assessed in this study. The overall success rate of the first ablation therapy was 74.3%. The success rate of the ablation therapy was 66% and 75% in metastatic group and non-metastatic group, respectively. Except the significant correlation between the number of pathologic lymph nodes and the success of ablation (p=0.025), there was no other significant correlation between the patient/disease related factors and the success of ablation therapy.
Significant correlation between the number of the pathologic lymph nodes and the ablation therapy performance can also be due to statistical error because of the limited sample size. There was no significant correlation between other patient/disease related prognostic factors and the success of ablation therapy.
None declared.
探讨与患者及疾病相关的因素对接受碘 - 131消融治疗的分化型甲状腺癌患者消融治疗成功与否有无影响。
选取2007年7月至2009年9月间接受甲状腺切除术后接受碘 - 131消融治疗的所有分化型甲状腺癌患者。患者至少随访6个月。记录患者的年龄、性别、肿瘤类型、有无包膜侵犯、肿瘤大小、肿瘤数量、肿瘤位置、甲状腺包膜侵犯情况、淋巴/血管侵犯情况、有无转移性淋巴结、手术类型、消融前甲状腺球蛋白(Tg)、抗甲状腺球蛋白抗体(AntiTg)、促甲状腺激素(TSH)值、评估转移性疾病的检查(甲状腺及骨闪烁扫描、颈部及腹部超声、胸部及脑部计算机断层扫描)、给药剂量、消融后碘 - 131全身扫描(WBS)及诊断性碘 - 131 WBS、颈部超声检查、第6个月时的Tg及AntiTg值。将第6个月诊断性碘 - 131 WBS图像上有无残留甲状腺活性作为消融成功的标准。
本研究共评估了191例分化型甲状腺癌患者。首次消融治疗的总体成功率为74.3%。转移性组和非转移性组的消融治疗成功率分别为66%和75%。除病理淋巴结数量与消融成功率之间存在显著相关性(p = 0.025)外,患者/疾病相关因素与消融治疗成功率之间无其他显著相关性。
病理淋巴结数量与消融治疗效果之间的显著相关性也可能是由于样本量有限导致的统计误差。其他患者/疾病相关的预后因素与消融治疗成功率之间无显著相关性。
未声明。